Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
This product is a BaF3 stable cell line. It stably expresses Human JAK2 & EPOR (V617F) to provide cell models for research and screening applications.
Product Information
Target Protein
JAK2 & EPOR (V617F)
Target Protein Species
Human
Accession Number
NM_001322194.2
Protein Tag
Tag-free
Host Cell Type
BaF3
Target Classification
Kinases/Enzyme
Target Family
Kinases/Enzyme
Target Research Area
Cardiovascular Research
Related Diseases
Polycythemia Vera; Thrombocythemia
Product Properties
Morphology
Suspension
Assay Types
Drug screening and biological assays
Resistance
Puromycin
Stability
10 passages
Mycoplasma Testing
Negative
Biosafety Level
Level 1
Activity
Yes
Quantity
5x10⁶ cells
Form
Frozen cells
Freeze Medium
70% RPMI 1640 + 20% FBS + 10% DMSO
Culture Medium
RPMI 1640 + 10% FBS
Selective Antibiotic(s)
Regular antibiotics active against mycoplasmas, bacteria and fungi.
Handling Notes
Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance. Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line. Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
Incubation
37°C with 5% CO₂
Applications
Drug screening and biological assays
Application Notes
Cells were plated in a 384-well plate and incubated overnight at 37°C and 5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control for high-throughput drugs screening andfunctional assays.
Use Restrictions
These cells are distributed for research use only.
Shipping
Dry ice
Storage
Liquid nitrogen
Target
Full Name
Janus kinase 2
Introduction
This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms.
Alternative Names
JTK10; tyrosine-protein kinase JAK2; JAK-2; Janus kinase 2 (a protein tyrosine kinase)